The CARB-X 2022-2023 funding rounds have three distinct product themes.
Please check back for details on future funding round themes.
The scope is restricted to oral products addressing specific syndromes and causative agents possible, including:
- Stepdown for respiratory tract infections caused primarily by Gram-negative pathogens, including antibiotic-resistant strains (see Target Product Profile);
- Safe therapy for infections caused primarily by Gram-positive organisms, including antibiotic-strains (see Target Product Profile); or
- Safe therapy for urinary tract infections, including those caused by antibiotic-resistant bacteria (see Target Product Profile).
In all cases, activity against multidrug-resistant isolates of pathogens specified in the Target Product Profiles is essential.
Vaccines for neonatal sepsis:
The scope is restricted to vaccines focused on the prevention of neonatal sepsis, targeting one or more of the following organisms (see Target Product Profile):
- Klebsiella pneumoniae (highest priority);
- Escherichia coli (ETEC or urinary);
- Acinetobacter baumannii; and
- Staphylococcus aureus.
While a maternal vaccine is sought, an additional commercial indication may be considered.
The scope is open to products that address Neisseria gonorrhoeae, including, for example:
- Oral therapeutics, or in special cases, IM therapeutic (see Target Product Profile);
- Low-cost vaccines (see Target Product Profile); and
- Rapid diagnostics (see Target Product Profile).
Therapeutic and vaccine products must address both drug-sensitive and drug-resistant scenarios.